Dear Colleague,
Welcome to Applied Clinical Trials' 2007 Directory & Buyers Guide. Enclosed within these pages is a comprehensive list of key leaders and resources in the clinical trials industry. We know you will find a great deal of information to facilitate your search for suppliers and outsourcers of Clinical Packaging, Consulting, CROs, Contract Research Services, Information Technology, IRBs, Laboratories and Laboratory Supplies, Subject Recruitment, Training and Education, and Career Recruitment and Staffing—the latest addition to the Guide.
Wayne K. Blow
The clinical trials community is continually growing, and it is important to keep up with the changing environment. The purpose of the Directory & Buyers Guide is to keep you abreast of the changes taking place, whether they are in clinical trials monitoring, specialty labs, EDC suppliers, software developers or training and education. Clinical trials require strategic partners and outsourcers who will provide solutions to challenges, and they can be easily accessed within these pages.
Whether you are looking for a particular company or researching CROs, you will find what you need quickly in the ACT Directory & Buyers Guide. While clinical trials colleagues communicate with you via the Internet, direct mail or at workshops and conferences, this single source, desktop print directory will have distinct advantages. The directory is set up with a comprehensive category list and an alphabetized index. The directory also includes a calendar of upcoming clinical trials events.
I hope our ACT 2007 Directory & Buyers Guide proves to be an essential and invaluable part of your desktop reference tools.
Best regards,
Wayne K. Blow
Publisher, Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.